{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T22:23:46Z","timestamp":1773527026878,"version":"3.50.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G0B9819N"],"award-info":[{"award-number":["G0B9819N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s40261-024-01384-w","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T16:02:07Z","timestamp":1723478527000},"page":"611-627","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Budget Impact of Disease-Modifying Treatments and a CRISPR Gene-Edited Therapy for Sickle Cell Disease"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0149-9213","authenticated-orcid":false,"given":"Khadidja","family":"Abdallah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Huys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen J.","family":"Claes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9512-2005","authenticated-orcid":false,"given":"Steven","family":"Simoens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,12]]},"reference":[{"issue":"1","key":"1384_CR1","doi-asserted-by":"publisher","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","volume":"4","author":"GJ Kato","year":"2018","unstructured":"Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, et al. Sickle cell disease. Nat Rev Dis Primers. 2018;4(1):18010.","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"1384_CR2","doi-asserted-by":"publisher","first-page":"e687","DOI":"10.1016\/S2352-3026(23)00182-5","volume":"10","author":"MDM Ma\u00f1\u00fa Pereira","year":"2023","unstructured":"Ma\u00f1\u00fa Pereira MDM, Colombatti R, Alvarez F, Bartolucci P, Bento C, Brunetta AL, et al. Sickle cell disease landscape and challenges in the EU: the ERN-EuroBloodNet perspective. Lancet Haematol. 2023;10(8):e687\u201394.","journal-title":"Lancet Haematol."},{"issue":"8","key":"1384_CR3","doi-asserted-by":"publisher","first-page":"e585","DOI":"10.1016\/S2352-3026(23)00118-7","volume":"10","author":"AM Thomson","year":"2023","unstructured":"Thomson AM, McHugh TA, Oron AP, Teply C, Lonberg N, Vilchis Tella V, et al. Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000\u20132021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Haematol. 2023;10(8):e585\u201399.","journal-title":"Lancet Haematol"},{"key":"1384_CR4","first-page":"135","volume":"6","author":"O Ketelslegers","year":"2015","unstructured":"Ketelslegers O, Eyskens F, Boemer F, Bours V, Minon JM, Gulbis B. Epidemiological data on sickle cell disease in Belgium. Belgian J Hematol. 2015;6:135\u201341.","journal-title":"Belgian J Hematol."},{"issue":"3","key":"1384_CR5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1182\/bloodadvances.2021006281","volume":"7","author":"KM Johnson","year":"2023","unstructured":"Johnson KM, Jiao B, Ramsey SD, Bender MA, Devine B, Basu A. Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance. Blood Adv. 2023;7(3):365\u201374.","journal-title":"Blood Adv"},{"issue":"10091","key":"1384_CR6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0140-6736(17)30193-9","volume":"390","author":"RE Ware","year":"2017","unstructured":"Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet. 2017;390(10091):311\u201323.","journal-title":"Lancet"},{"issue":"2","key":"1384_CR7","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/pbc.24176","volume":"59","author":"JA Panepinto","year":"2012","unstructured":"Panepinto JA, Bonner M. Health-related quality of life in sickle cell disease: past, present, and future. Pediatr Blood Cancer. 2012;59(2):377\u201385.","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"1384_CR8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41573-018-0003-2","volume":"18","author":"MJ Telen","year":"2019","unstructured":"Telen MJ, Malik P, Vercellotti GM. Therapeutic strategies for sickle cell disease: towards a multi-agent approach. Nat Rev Drug Discov. 2019;18(2):139\u201358.","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"1384_CR9","first-page":"CD002202","volume":"9","author":"AE Rankine-Mullings","year":"2022","unstructured":"Rankine-Mullings AE, Nevitt SJ. Hydroxyurea (hydroxycarbamide) for sickle cell disease. Cochrane Database Syst Rev. 2022;9(9):CD002202.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1384_CR10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1046\/j.1526-0968.2002.00396.x","volume":"6","author":"CM Danielson","year":"2002","unstructured":"Danielson CM. The role of red blood cell exchange transfusion in the treatment and prevention of complications of sickle cell disease. Ther Apher. 2002;6(1):24\u201331.","journal-title":"Ther Apher"},{"issue":"11","key":"1384_CR11","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1002\/pbc.25608","volume":"62","author":"PQ L\u00ea","year":"2015","unstructured":"L\u00ea PQ, Gulbis B, Dedeken L, Dupont S, Vanderfaeillie A, Heijmans C, et al. Survival among children and adults with sickle cell disease in Belgium: benefit from hydroxyurea treatment. Pediatr Blood Cancer. 2015;62(11):1956\u201361.","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"1384_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.bmt.1701291","volume":"22","author":"C Vermylen","year":"1998","unstructured":"Vermylen C, Cornu G, Ferster A, Brichard B, Ninane J, Ferrant A, et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant. 1998;22(1):1\u20136.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"1384_CR13","doi-asserted-by":"publisher","first-page":"e201737","DOI":"10.1001\/jamanetworkopen.2020.1737","volume":"3","author":"F Farooq","year":"2020","unstructured":"Farooq F, Mogayzel PJ, Lanzkron S, Haywood C, Strouse JJ. Comparison of US Federal and Foundation Funding of research for sickle cell disease and cystic fibrosis and factors associated with research productivity. JAMA Netw Open. 2020;3(3):e201737.","journal-title":"JAMA Netw Open"},{"key":"1384_CR14","unstructured":"European Medicines Agency. Oxbryta. 2022.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/oxbryta. Accessed 21 Mar 2023."},{"key":"1384_CR15","unstructured":"European Medicines Agency. Adakveo. 2020.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/adakveo. Accessed 21 Mar 2023."},{"issue":"6","key":"1384_CR16","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.hoc.2022.06.008","volume":"36","author":"P Rai","year":"2022","unstructured":"Rai P, Desai PC, Ataga KI. The evolving landscape of drug therapies for sickle cell disease. Hematol Oncol Clin North Am. 2022;36(6):1285\u2013312.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"5","key":"1384_CR17","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1056\/NEJMoa1611770","volume":"376","author":"KI Ataga","year":"2016","unstructured":"Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, et al. Crizanlizumab for the Prevention of pain crises in sickle cell disease. N Engl J Med. 2016;376(5):429\u201339.","journal-title":"N Engl J Med"},{"key":"1384_CR18","unstructured":"European Medicines Agency. Revocation of authorisation for sickle cell disease medicine Adakveo. 2023. https:\/\/www.ema.europa.eu\/en\/news\/revocation-authorisation-sickle-cell-disease-medicine-adakveo. Accessed 22 Sept 2023."},{"issue":"5","key":"1384_CR19","doi-asserted-by":"publisher","first-page":"e323","DOI":"10.1016\/S2352-3026(21)00059-4","volume":"8","author":"J Howard","year":"2021","unstructured":"Howard J, Ataga KI, Brown RC, Achebe M, Nduba V, El-Beshlawy A, et al. Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2021;8(5):e323\u201333.","journal-title":"Lancet Haematol."},{"issue":"3","key":"1384_CR20","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2031054","volume":"384","author":"H Frangoul","year":"2020","unstructured":"Frangoul H, Altshuler D, Cappellini MD, Chen Y-S, Domm J, Eustace BK, et al. CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia. N Engl J Med. 2020;384(3):252\u201360.","journal-title":"N Engl J Med"},{"key":"1384_CR21","unstructured":"ClinicalTrials.gov. A safety and efficacy study evaluating CTX001 in subjects with severe sickle cell disease (NCT03745287): National Institutes of Health: National Center for Biotechnology Information.; cited. 2022. https:\/\/clinicaltrials.gov\/study\/NCT03745287. Accessed 19 Sept 2023."},{"issue":"1","key":"1384_CR22","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13023-018-0927-y","volume":"13","author":"M Szegedi","year":"2018","unstructured":"Szegedi M, Zelei T, Arickx F, Bucsics A, Cohn-Zanchetta E, F\u00fcrst J, et al. The European challenges of funding orphan medicinal products. Orphanet J Rare Dis. 2018;13(1):184.","journal-title":"Orphanet J Rare Dis"},{"key":"1384_CR23","unstructured":"Dunleavy K. With the pricing situation 'untenable' in Europe, bluebird will wind down its operations in the 'broken' market: Fierce Pharma; cited. 2021. https:\/\/www.fiercepharma.com\/pharma\/situation-untenable-bluebird-will-wind-down-its-operations-broken-europe. Accessed 22 Sept 2023."},{"key":"1384_CR24","unstructured":"Cleemput I, Neyt M, Van De Sande S, Thiry N. Belgian guidelines for economic evaluations and budget impact analyses: second edition. Health Technology Assessment (HTA). Brussels: Belgian Health Care Knowledge Centre (KCE); 2012. Report No.: 183C."},{"issue":"1","key":"1384_CR25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","volume":"17","author":"SD Sullivan","year":"2014","unstructured":"Sullivan SD, Mauskopf JA, Augustovski F, Jaime Caro J, Lee KM, Minchin M, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):5\u201314.","journal-title":"Value Health."},{"key":"1384_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.630949","volume":"12","author":"K Abdallah","year":"2021","unstructured":"Abdallah K, Huys I, Claes K, Simoens S. Methodological quality assessment of budget impact analyses for orphan drugs: a systematic review. Front Pharmacol. 2021;12: 630949.","journal-title":"Front Pharmacol"},{"key":"1384_CR27","unstructured":"European Medicines Agency. Adakveo (crizanlizumab) EU\/3\/12\/1034\u2014orphan designation for treatment of sickle cell disease. 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu-3-12-1034. Accessed 10 Jul 2024."},{"key":"1384_CR28","unstructured":"European Medicines Agency. Casgevy (Exagamglogene autotemcel). 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/casgevy. Accessed 10 Jul 2024."},{"key":"1384_CR29","unstructured":"ClinicalTrials.gov. A phase III, multicenter, randomized, placebo controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg\/kg) versus placebo, with or without hydroxyurea\/hydroxycarbamide therapy, in adolescent and adult sickle cell disease patients with frequent vaso-occlusive crises novartis pharmaceuticals not yet recruiting]. 2024. https:\/\/clinicaltrials.gov\/study\/NCT06439082. Accessed 10 Jul 2024."},{"key":"1384_CR30","unstructured":"Novartis. European Commission (EC) adopts decision endorsing CHMP recommendation to revoke the conditional marketing authorization for Adakveo\u00ae (crizanlizumab). 2023. https:\/\/www.novartis.com\/news\/european-commission-ec-adopts-decision-endorsing-chmp-recommendation-revoke-conditional-marketing-authorization-adakveo-crizanlizumab. Accessed 10 Jul 2024."},{"key":"1384_CR31","unstructured":"National Institute for health and Disability Insurance (NIHDI-RIZIV-INAMI). Onbeantwoorde medische behoeften\u2014Unmet Medical Need. 2024. https:\/\/www.riziv.fgov.be\/nl\/thema-s\/verzorging-kosten-en-terugbetaling\/wat-het-ziekenfonds-terugbetaalt\/geneesmiddelen\/geneesmiddel-terugbetalen\/onbeantwoorde-medische-behoeften-unmet-medical-need. Accessed 10 Jul 2024."},{"key":"1384_CR32","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. OXBRYTA (voxelotor) - An\u00e9mie h\u00e9molytique s\u00e9v\u00e8re. 2022. https:\/\/www.has-sante.fr\/jcms\/p_3361556\/fr\/oxbryta-voxelotor-anemie-hemolytique-severe. Accessed 10 Jul 2024."},{"key":"1384_CR33","unstructured":"National Institute for Health and Care Excellence (NICE). Voxelotor for treating haemolytic anaemia caused by sickle cell disease. 2024. https:\/\/www.nice.org.uk\/guidance\/ta981\/chapter\/2-Information-about-voxelotor. Accessed 10 Jul 2024."},{"key":"1384_CR34","unstructured":"National Institute for Health and Care Excellence (NICE). Exagamglogene autotemcel for treating sickle cell disease [ID4016]. 2024. https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta11249\/documents. Accessed 10 Jul 2024."},{"issue":"Supplement 1","key":"1384_CR35","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.1182\/blood-2021-145403","volume":"138","author":"S Wambacq","year":"2021","unstructured":"Wambacq S, Gulbis B, Benghiat FS, Brichard B, Annelyse B, Dedeken L, et al. Factors influencing change in MCV and age at transplantation in the Belgian sickle cell disease registry. Blood. 2021;138(Supplement 1):4171.","journal-title":"Blood"},{"key":"1384_CR36","unstructured":"CRISPR Therapeutics. CRISPR Therapeutics and Vertex Pharmaceuticals Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to CTX001\u2122 for the treatment of sickle cell disease. 2020. https:\/\/crisprtx.com\/about-us\/press-releases-and-presentations\/crispr-therapeutics-and-vertex-pharmaceuticals-announce-priority-medicines-prime-designation-granted-by-the-european-medicines-agency-ema-to-ctx001-for-the-treatment-of-sickle-cell-disease. Accessed 25 Sep 2023."},{"issue":"Supplement 1","key":"1384_CR37","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1182\/blood-2021-153136","volume":"138","author":"J Kanter","year":"2021","unstructured":"Kanter J, Hellemann G, Cohen AJ, Manwani D, Idowu M, Guarino S, et al. Early evaluation of the use of crizanlizumab in sickle cell disease: a national alliance of sickle cell centers study. Blood. 2021;138(Supplement 1):3113.","journal-title":"Blood"},{"key":"1384_CR38","unstructured":"Belgian Center for Pharmacotherapeutic Information (BCFI). 2023. https:\/\/www.bcfi.be\/nl\/. Accessed 19 Sept 2023."},{"key":"1384_CR39","unstructured":"National Institute for Health and Disability Insurance (NIHDI). Honoraria, prijzen en tegemoetkomingen van artsen\u2014Raadplegingen en bezoeken 2023.https:\/\/www.riziv.fgov.be\/nl\/themas\/kost-terugbetaling\/door-ziekenfonds\/individuele-verzorging\/honoraires\/Paginas\/arts-deel1.aspx. Accessed 21 Sept 2023."},{"key":"1384_CR40","unstructured":"National Institute for Health and Disability Insurance (NIHDI-RIZIV-INAMI). Terugbetaling van menselijk bloed en labiele bloedproducten. 2022. https:\/\/www.riziv.fgov.be\/nl\/themas\/kost-terugbetaling\/door-ziekenfonds\/gezondheidsproducten\/Paginas\/terugbetaling-menselijk-bloed-labiele-bloedproducten.aspx. Accessed 19 Sept 2023."},{"key":"1384_CR41","unstructured":"National Institute for Health and Disability Insurance (NIHDI-RIZIV-INAMI). Nationale overeenkomst tussen de verpleeginrichtingen en de verzekeringsinstellingen 2020.https:\/\/www.riziv.fgov.be\/nl\/professionals\/verzorgingsinstellingen-en-diensten\/ziekenhuizen\/verzorging-in-ziekenhuizen#nationale-overeenkomsten-met-ziekenhuizen-en-verzekeringsinstellingen. Accessed 29 Sept 2023."},{"key":"1384_CR42","unstructured":"UMC Utrecht. Tarieven onderlinge dienstverlening 2023. 2023. https:\/\/assets-eu-01.kc-usercontent.com\/546dd520-97db-01b7-154d-79bb6d950a2d\/057f37de-4795-499d-a84b-4ffd608f3b4b\/ODV%20tarieven%202023%20versie%20website%20UMC%20Utrecht.pdf. Accessed 19 Sept 2023."},{"key":"1384_CR43","unstructured":"Isala Hospitals. Tarieven onderlinge dienstverlening andere ziekenhuizen. 2018. https:\/\/www.isala.nl\/media\/25870\/tarieven-onderlinge-dienstverlening-andere-ziekenhuizen-2018.pdf. Accessed 19 Sept 2023."},{"key":"1384_CR44","unstructured":"Pharmaceutical Information Library (PHiL). 2023. https:\/\/sso.apb.be\/MoreInformation\/phil?from=http%3A%2F%2Fphil.apb.be\/nl-BE\/&Culture=NL-BE. Accessed 19 Sept 2023."},{"key":"1384_CR45","unstructured":"BOC Healthcare Ireland. Medical gases price list (ex. VAT). 2023. https:\/\/www.boconline.ie\/en\/images\/IRE-HLC-Medical-Gas-Price-List_tcm674-615889.pdf. Accessed 21 Sept 2023."},{"issue":"9","key":"1384_CR46","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/j.1553-2712.1995.tb03276.x","volume":"2","author":"P Gruber","year":"1995","unstructured":"Gruber P, Kwiatkowski T, Silverman R, Flaster E, Auerbach C. Time to equilibration of oxygen saturation using pulse oximetry. Acad Emerg Med. 1995;2(9):810\u20135.","journal-title":"Acad Emerg Med"},{"key":"1384_CR47","unstructured":"National Institute for Health and Disability Insurance (NIHDI-RIZIV-INAMI). Verpleegdagprijzen ziekenhuizen. 2023. https:\/\/www.inami.fgov.be\/nl\/themas\/kost-terugbetaling\/door-ziekenfonds\/verzorging-ziekenhuizen\/Paginas\/verpleegdagprijzen-ziekenhuizen.aspx. Accessed 21 Sept 2023."},{"key":"1384_CR48","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/978-3-319-41912-1_4","volume-title":"Hematologic abnormalities and acute lung syndromes","author":"JR Sysol","year":"2017","unstructured":"Sysol JR, Machado R. Sickle cell disease and acute chest syndrome: epidemiology, diagnosis, management, outcomes. In: Hematologic abnormalities and acute lung syndromes. Cham: Springer; 2017. p. 67\u201387. https:\/\/doi.org\/10.1007\/978-3-319-41912-1_4."},{"issue":"6","key":"1384_CR49","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1089\/hum.2018.178","volume":"30","author":"S Coquerelle","year":"2019","unstructured":"Coquerelle S, Ghardallou M, Rais S, Taupin P, Touzot F, Boquet L, et al. Innovative curative treatment of beta thalassemia: cost-efficacy analysis of gene therapy versus allogenic hematopoietic stem-cell transplantation. Hum Gene Ther. 2019;30(6):753\u201361.","journal-title":"Hum Gene Ther"},{"key":"1384_CR50","unstructured":"Zorginstituut Nederland. Crizanlizumab (Adakveo). 2023. https:\/\/www.horizonscangeneesmiddelen.nl\/geneesmiddelen\/crizanlizumab-cardiovasculaire-aandoeningen-overige_niet-oncologische_hematologische_medicatie\/versie4?lang=nl. Accessed 21 Sept 2023."},{"issue":"Supplement_1","key":"1384_CR51","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1182\/blood-2019-123965","volume":"134","author":"J Kanter","year":"2019","unstructured":"Kanter J, Liles DK, Smith-Whitley K, Brown C, Kutlar A, Elliott B, et al. Crizanlizumab 5.0 mg\/kg exhibits a favorable safety profile in patients with sickle cell disease: pooled data from two phase II studies. Blood. 2019;134(Supplement_1):991.","journal-title":"Blood"},{"issue":"6","key":"1384_CR52","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1182\/bloodadvances.2022008209","volume":"7","author":"J Kanter","year":"2023","unstructured":"Kanter J, Brown RC, Norris C, Nair SM, Kutlar A, Manwani D, et al. Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease. Blood Adv. 2023;7(6):943\u201352.","journal-title":"Blood Adv"},{"key":"1384_CR53","unstructured":"Zorginstituut Nederland. Voxelotor (oxbryta). 2023. https:\/\/www.horizonscangeneesmiddelen.nl\/geneesmiddelen\/voxelotor-cardiovasculaire-aandoeningen-overige_niet-oncologische_hematologische_medicatie\/versie7. Accessed 21 Sept 2023."},{"key":"1384_CR54","unstructured":"American Society of Hematology. Bluebird bio ends commercial operations in Europe. 2021. https:\/\/ashpublications.org\/ashclinicalnews\/news\/5779\/Bluebird-Bio-Ends-Commercial-Operations-in-Europe. Accessed 19 Sept 2023."},{"key":"1384_CR55","unstructured":"Campbell Collaboration. CCEMG\u2014EPPI-Centre Cost Converter. 2019. https:\/\/eppi.ioe.ac.uk\/costconversion\/default.aspx. Accessed 21 Sept 2023."},{"issue":"10","key":"1384_CR56","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1001\/jama.2014.10517","volume":"312","author":"BP Yawn","year":"2014","unstructured":"Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312(10):1033\u201348.","journal-title":"JAMA"},{"key":"1384_CR57","unstructured":"Sickle Cell Society. Standards for the clinical care of adults with sickle cell disease in the UK 2018. https:\/\/www.sicklecellsociety.org\/wp-content\/uploads\/2018\/05\/Standards-for-the-Clinical-Care-of-Adults-with-Sickle-Cell-in-the-UK-2018.pdf. Accessed 19 Sept 2023."},{"key":"1384_CR58","unstructured":"Efira A., Azerad M.A., Devos T. Sickle cell disease: regular follow-up of adultpatients: Red Blood Cell Disorders Committee of the Belgian Hematological Society; cited. 2012. https:\/\/bhs.be\/storage\/app\/media\/uploaded-files\/Management%20SCD%20FU%20adults%202012.pdf. Accessed 19 Sept 2023."},{"issue":"4","key":"1384_CR59","first-page":"165","volume":"10","author":"A van Genechten","year":"2019","unstructured":"van Genechten A, Vanderfaeillie A, Azerad M-A, Kieffer D, Labarque V, Gulbis B, et al. BHS clinical guidelines on the management of acute complications in sickle cell disease. Belgian J Hematol. 2019;10(4):165\u20138.","journal-title":"Belgian J Hematol."},{"key":"1384_CR60","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g1765","volume":"348","author":"V Brousse","year":"2014","unstructured":"Brousse V, Makani J, Rees DC. Management of sickle cell disease in the community. BMJ. 2014;348: g1765.","journal-title":"BMJ"},{"issue":"4","key":"1384_CR61","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s40258-021-00714-9","volume":"20","author":"R Koleva-Kolarova","year":"2022","unstructured":"Koleva-Kolarova R, Buchanan J, Vellekoop H, Huygens S, Versteegh M, M\u00f6lken MR-V, et al. Financing and reimbursement models for personalised medicine: a systematic review to identify current models and future options. Appl Health Econ Health Policy. 2022;20(4):501\u201324.","journal-title":"Appl Health Econ Health Policy"},{"key":"1384_CR62","unstructured":"ClinicalTrials.gov. Study to evaluate the effect of voxelotor administered orally to patients with sickle cell disease (GBT_HOPE) 2023. https:\/\/clinicaltrials.gov\/study\/NCT03036813?tab=results. Accessed 10 Jul 2024."},{"key":"1384_CR63","unstructured":"Institute for Clinical and Economic Review (ICER). Crizanlizumab, voxelotor, and L-glutamine for sickle cell disease: effectiveness and value. 2021. https:\/\/icer.org\/wp-content\/uploads\/2021\/02\/ICER_SCD_Evidence-Report_031220-FOR-PUBLICATION.pdf. Accessed 23 Sept 2023."},{"issue":"9","key":"1384_CR64","first-page":"2476","volume":"108","author":"V Brousse","year":"2023","unstructured":"Brousse V, Bernaudin F, Melaine A, Goguillot M, Gallagher M, Benard S, et al. Severity and burden of sickle cell disease in France: a nationwide real-world study. Haematologica. 2023;108(9):2476\u201386.","journal-title":"Haematologica"},{"issue":"6","key":"1384_CR65","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1001\/jamapediatrics.2020.7140","volume":"175","author":"P DeMartino","year":"2021","unstructured":"DeMartino P, Haag MB, Hersh AR, Caughey AB, Roth JA. A budget impact analysis of gene therapy for sickle cell disease: the medicaid perspective. JAMA Pediatr. 2021;175(6):617\u201323.","journal-title":"JAMA Pediatr"},{"key":"1384_CR66","unstructured":"Medicines and Healthcare products Regulatory Agency (MHRA). Voxelotor early access to medicines scheme: treatment protocol for healthcare professionals. 2022. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1096694\/Voxeltor__Treatment_protocol___Information_for_healthcare_professionals.pdf. Accessed 25 Sept 2023."},{"key":"1384_CR67","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. OXBRYTA (voxelotor)\u2014An\u00e9mie h\u00e9molytique D\u00c9CISION D'ACC\u00c8S PR\u00c9COCE. 2022. https:\/\/www.has-sante.fr\/jcms\/p_3348600\/fr\/oxbryta-voxelotor-anemie-hemolytique. Accessed 25 Sept 2023."},{"key":"1384_CR68","unstructured":"Christelijke Mutualiteit. Begroting voor gezondheidszorg 2023. 2022. https:\/\/www.cm.be\/media\/GezondheidSamenleving_5_begroting-voor-gezondheidszorg-2023_tcm47-78135.pdf. Accessed 23 Sept 2023."},{"key":"1384_CR69","unstructured":"Institute for Clinical and Economic Review (ICER). Assessing the effectiveness and value of drugs for rare conditions. 2017. https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_Assessing-the-Value-of-Drugs-for-Rare-Conditions_051017-1.pdf. Accessed 25 Sept 2023."},{"key":"1384_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.631527","author":"A Blonda","year":"2021","unstructured":"Blonda A, Denier Y, Huys I, Simoens S. How to value orphan drugs? A review of European value assessment frameworks. Front Pharmacol. 2021. https:\/\/doi.org\/10.3389\/fphar.2021.631527.","journal-title":"Front Pharmacol"},{"issue":"9","key":"1384_CR71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0291211","volume":"18","author":"F Galacteros","year":"2023","unstructured":"Galacteros F, Ethgen O, Beillat M. Modeling the public health impact of voxelotor in the management of sickle cell disease in France. PLoS ONE. 2023;18(9): e0291211.","journal-title":"PLoS ONE"},{"issue":"5","key":"1384_CR72","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1136\/jim-2021-002215","volume":"70","author":"M Idowu","year":"2022","unstructured":"Idowu M, Haque A, Williams EM, Sridhar A. Patient perception of voxelotor treatment benefit in sickle cell disease. J Investig Med. 2022;70(5):1316\u20139.","journal-title":"J Investig Med"},{"key":"1384_CR73","unstructured":"Global Blood Therapeutics. Overview of the sickle cell disease environment in select European countries. 2020. https:\/\/www.scribd.com\/document\/533457661\/Overview-of-the-Sickle-Cell-Disease-Environment-in-Select-European-Countries-October-2020. Accessed 25 Sept 2023."},{"issue":"2","key":"1384_CR74","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1586\/14737167.2016.1159958","volume":"16","author":"DR Faleiros","year":"2016","unstructured":"Faleiros DR, \u00c1lvares J, Almeida AM, de Ara\u00fajo VE, Andrade EI, Godman BB, et al. Budget impact analysis of medicines: updated systematic review and implications. Expert Rev Pharmacoecon Outcomes Res. 2016;16(2):257\u201366.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"1384_CR75","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40258-013-0064-7","volume":"12","author":"K van de Vooren","year":"2014","unstructured":"van de Vooren K, Duranti S, Curto A, Garattini L. A critical systematic review of budget impact analyses on drugs in the EU countries. Appl Health Econ Health Policy. 2014;12(1):33\u201340.","journal-title":"Appl Health Econ Health Policy"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01384-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-024-01384-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01384-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T10:27:09Z","timestamp":1724408829000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-024-01384-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":75,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1384"],"URL":"https:\/\/doi.org\/10.1007\/s40261-024-01384-w","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"22 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was funded by grant G0B9819N, received from the Research Foundation of Flanders (FWO, Fonds voor Wetenschappelijk Onderzoek). The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"K.A. does not report any conflicts of interest. S.S. has previously conducted research about market access of orphan drugs sponsored by the Belgian Health Care Knowledge Centre and by Genzyme (now Sanofi); he has participated in an orphan drug roundtable sponsored by Celgene; and is a member of the ISPOR Rare Disease Special Interest Group\u2019s Challenges in Research and Health Technology Assessment of Rare Disease Technologies Working Group, the International Working Group on Orphan Drugs, and the Innoval Working Group on Ultra-Rare Disorders. K.J.C.) has received consultancy fees from Alexion, Astellas, Astra Zeneca, and Sanofi. I.H. is currently partly seconded to the cabinet of Deputy Prime Minister and Minister for Social Affairs and Public Health of Belgium. She\u00a0has worked in collaboration with\u00a0RIZIV\/INAMI on the reformation of the Drug Reimbursement\u00a0procedures in Belgium.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data are available upon request to the corresponding author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"\u201cThe Research Ethics Committee UZ\/KU Leuven hereby grants favorable advice to the proposed study, as it was described in the protocol. The Commission is of the opinion that from an ethical standpoint there are no objections to the proposed study. The study was approved on 04-10-2022.\u201d Committee\u2019s reference number: MP021468","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent to participate in this study were obtained from all participants.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Informed consent to publish study findings were obtained from all participants.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"K.A. and S.S. thought of the concepts and designed the study; K.A. conducted the study. K.A. and K.J.C. coordinated data collection of the study; K.A. drafted the manuscript under supervision of S.S., I.H., and K.J.C.; S.S., I.H., and K.J.C. critically read, revised, and approved the submitted version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}